![Michael Mullette](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Shannon Klinger | M | 53 | 3 Jahre | |
Elizabeth Nabel | M | 72 | 3 Jahre | |
Amy Emerson | F | - |
Lykos Therapeutics PBC
![]() Lykos Therapeutics PBC BiotechnologyHealth Technology Part of Multidisciplinary Association for Psychedelic Studies, Lykos Therapeutics, Inc. is a public benefit corporation that focuses on developing and commercializing prescription psychedelics to provide better treatments for people with mental health conditions. The private company is based in San Jose, CA. Lykos Therapeutics aims to catalyze healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics, prioritizing public benefit above profit. The company was founded in 2014, and the CEO is Amy Emerson. | - |
Gisselle Acevedo | F | 66 |
Lykos Therapeutics PBC
![]() Lykos Therapeutics PBC BiotechnologyHealth Technology Part of Multidisciplinary Association for Psychedelic Studies, Lykos Therapeutics, Inc. is a public benefit corporation that focuses on developing and commercializing prescription psychedelics to provide better treatments for people with mental health conditions. The private company is based in San Jose, CA. Lykos Therapeutics aims to catalyze healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics, prioritizing public benefit above profit. The company was founded in 2014, and the CEO is Amy Emerson. | - |
Kate Cronin | F | 58 | 3 Jahre | |
Jason Pyle | M | - |
Lykos Therapeutics PBC
![]() Lykos Therapeutics PBC BiotechnologyHealth Technology Part of Multidisciplinary Association for Psychedelic Studies, Lykos Therapeutics, Inc. is a public benefit corporation that focuses on developing and commercializing prescription psychedelics to provide better treatments for people with mental health conditions. The private company is based in San Jose, CA. Lykos Therapeutics aims to catalyze healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics, prioritizing public benefit above profit. The company was founded in 2014, and the CEO is Amy Emerson. | - |
Jeffrey George | M | 51 |
Lykos Therapeutics PBC
![]() Lykos Therapeutics PBC BiotechnologyHealth Technology Part of Multidisciplinary Association for Psychedelic Studies, Lykos Therapeutics, Inc. is a public benefit corporation that focuses on developing and commercializing prescription psychedelics to provide better treatments for people with mental health conditions. The private company is based in San Jose, CA. Lykos Therapeutics aims to catalyze healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics, prioritizing public benefit above profit. The company was founded in 2014, and the CEO is Amy Emerson. | 2 Jahre |
Dan Grossman | M | - |
Lykos Therapeutics PBC
![]() Lykos Therapeutics PBC BiotechnologyHealth Technology Part of Multidisciplinary Association for Psychedelic Studies, Lykos Therapeutics, Inc. is a public benefit corporation that focuses on developing and commercializing prescription psychedelics to provide better treatments for people with mental health conditions. The private company is based in San Jose, CA. Lykos Therapeutics aims to catalyze healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics, prioritizing public benefit above profit. The company was founded in 2014, and the CEO is Amy Emerson. | 2 Jahre |
José M. Vega | M | - | 3 Jahre | |
Miriam Volat | F | - |
Lykos Therapeutics PBC
![]() Lykos Therapeutics PBC BiotechnologyHealth Technology Part of Multidisciplinary Association for Psychedelic Studies, Lykos Therapeutics, Inc. is a public benefit corporation that focuses on developing and commercializing prescription psychedelics to provide better treatments for people with mental health conditions. The private company is based in San Jose, CA. Lykos Therapeutics aims to catalyze healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics, prioritizing public benefit above profit. The company was founded in 2014, and the CEO is Amy Emerson. | - |
Rick Doblin | M | - |
Lykos Therapeutics PBC
![]() Lykos Therapeutics PBC BiotechnologyHealth Technology Part of Multidisciplinary Association for Psychedelic Studies, Lykos Therapeutics, Inc. is a public benefit corporation that focuses on developing and commercializing prescription psychedelics to provide better treatments for people with mental health conditions. The private company is based in San Jose, CA. Lykos Therapeutics aims to catalyze healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics, prioritizing public benefit above profit. The company was founded in 2014, and the CEO is Amy Emerson. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Lori M. Henderson | F | 62 | 3 Jahre | |
Paul Burton | M | 55 | 2 Jahre | |
Corinne Le Goff | M | 58 | 1 Jahre | |
Tal Zaks | M | 58 | 6 Jahre | |
Marcello Damiani | M | 54 | 7 Jahre | |
Dawn McCollough | F | - |
Lykos Therapeutics PBC
![]() Lykos Therapeutics PBC BiotechnologyHealth Technology Part of Multidisciplinary Association for Psychedelic Studies, Lykos Therapeutics, Inc. is a public benefit corporation that focuses on developing and commercializing prescription psychedelics to provide better treatments for people with mental health conditions. The private company is based in San Jose, CA. Lykos Therapeutics aims to catalyze healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics, prioritizing public benefit above profit. The company was founded in 2014, and the CEO is Amy Emerson. | 3 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 17 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Michael Mullette
- Persönliches Netzwerk